HRS2398

· Shanghai Hengrui Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HRS2398, covering 2024-07-05 to 2024-12-18. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors [Phase 1]